10.1038/s41375-021-01485-x - Efficacy and safety in a 4-year follo...

This document has been corrected

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

10.1038/s41375-021-01485-x

Published Online: 2022-01-01

Journal: Leukemia•Publisher: Springer Science and Business Media LLC

Authors: Alan Skarbnik•Ann Janssens•Emmanuelle Ferrant•Florence Cymbalista•George Follows•Gillian Corbett•Ian W. Flinn•Jeff P. Sharman•Jennifer A. Woyach•John C. Byrd•John M. Pagel•Karin Karlsson•Laura Maria Fogliatto•Manali Kamdar•Miklos Egyed•Min Hui Wang•Paolo Ghia•Patricia Walker•Renata Walewska•Steven Coutre•Talha Munir•Ting Yu•Veerendra Munugalavadla•Versha Banerji•William G. Wierda•Wojciech Jurczak•Yair Herishanu

This document has been corrected

10.1038/s41375-021-01485-x

Published Online: 2022-01-01

Journal: Leukemia

NOW

2024-12-03•Correction

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

10.1038/s41375-024-02487-1

* information provided by CrossRef

2024-12-03•Correction

10.1038/s41375-024-02487-1

* information provided by CrossRef

2022-01-01•Published

2024-12-03•Correction

10.1038/s41375-024-02487-1

* information provided by CrossRef

This document has been corrected

10.1038/s41375-021-01485-x

Published Online: 2022-01-01

Journal: Leukemia•Publisher: Springer Science and Business Media LLC